Key Points

  • Options pricing implies Snowflake shares could move as much as 10.5% in either direction following earnings.
  • Wall Street expects second-quarter revenue of $1.48 billion and adjusted earnings of 45 cents per share, both approximately 30% above the year-ago period.
  • Analyst sentiment remains strongly bullish, but the stock's roughly 50% 2026 rally leaves little room for disappointment.
hero

Snowflake is heading into its latest earnings report with investor expectations elevated after a powerful 2026 rally and growing enthusiasm around its artificial intelligence strategy. Options markets are pricing a potential move of as much as 10.5% in either direction by the end of the week, putting the cloud database company’s upcoming results under significant scrutiny. The reaction will likely depend not only on quarterly numbers but also on whether management can demonstrate that AI demand is translating into sustainable growth.

Options Market Signals a Major Post-Earnings Move

Snowflake is scheduled to release its quarterly results after Wednesday’s closing bell. Based on current options pricing, shares could move approximately 10.5% higher or lower by the end of the week. Using Monday’s closing price as the reference point, such a move could push the stock toward $361 or below $297, creating a wide trading range around the earnings event.

The magnitude of the implied move reflects the uncertainty surrounding a company whose valuation has expanded alongside investor expectations for AI-driven growth. Snowflake shares have gained roughly 50% since the beginning of the year, making the earnings report an important test of whether fundamentals can continue supporting the rally.

AI Strategy Remains Central to the Investment Case

Investor enthusiasm has been reinforced by Snowflake’s expanding AI ambitions and its major commercial relationship with Amazon. Shares surged more than 35% in a single session in May following stronger-than-expected results, an improved outlook and news of a $6 billion deal with Amazon.

The latest earnings report will provide investors with another opportunity to assess whether that optimism is translating into accelerating demand. Analysts expect Snowflake to report second-quarter revenue of approximately $1.48 billion and adjusted earnings of 45 cents per share, representing roughly 30% year-over-year growth for both measures.

Wall Street Raises the Bar

Analyst sentiment has also become more constructive heading into the results. Oppenheimer, Bank of America, Deutsche Bank and UBS have recently raised their price targets. Bank of America said it has developed greater conviction that demand for Snowflake remains strong and that the company can continue monetizing its AI products.

The consensus remains heavily tilted toward the bullish side. Of 15 analysts tracked by Visible Alpha, 13 recommend buying the stock while two maintain neutral ratings. The average price target stands at $361, implying approximately 9% upside from Monday’s closing level.

What Investors Will Watch Next

The central question is whether Snowflake can exceed already optimistic expectations rather than simply deliver another solid quarter. Strong revenue growth, evidence of sustained AI-product adoption and constructive guidance could reinforce the current valuation and potentially send shares toward a new five-year high. Conversely, any indication that AI monetization is progressing more slowly than investors anticipate could trigger a sharp repricing, particularly given the stock’s substantial gains this year.

With options markets already anticipating a double-digit percentage move, Snowflake’s earnings are likely to become a broader test of investor confidence in AI-enabled enterprise software. The immediate market reaction may depend less on the headline results than on management’s ability to demonstrate that elevated expectations are supported by durable demand and improving commercial momentum.

 

 


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures?
    • Lior mor
    • •
    • 7 Min Read
    • •
    • ago 12 hours

    SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures? SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures?

    Tesla shares advanced on October 9 after new figures showed continued growth in sales of vehicles produced at the company’s

    • ago 12 hours
    • •
    • 7 Min Read

    Tesla shares advanced on October 9 after new figures showed continued growth in sales of vehicles produced at the company’s

    SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains
    • Lior mor
    • •
    • 6 Min Read
    • •
    • ago 1 day

    SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains

    Indian shares were poised to recover at the open on Friday after a sharp selloff pushed benchmark indexes to multi-year

    • ago 1 day
    • •
    • 6 Min Read

    Indian shares were poised to recover at the open on Friday after a sharp selloff pushed benchmark indexes to multi-year

    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.
    • omer bar
    • •
    • 6 Min Read
    • •
    • ago 1 day

    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments. SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    • ago 1 day
    • •
    • 6 Min Read

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 1 day

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a

    • ago 1 day
    • •
    • 6 Min Read

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a